Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA
Siamak Daneshmand(Unknown), Gary D. Steinberg(Rush University Medical Center), Cheryl T. Lee(The Ohio State University Wexner Medical Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Kamal S. Pohar(The Ohio State University), Michael S. Cookson(University of Oklahoma Health Sciences Center), Badrinath R. Konety(Allina Health), Anne Schuckman(University of Southern California), Leonard G. Gomella(Thomas Jefferson University), Raj S. Pruthi(University of North Carolina at Chapel Hill), Bernard H. Bochner(Memorial Sloan Kettering Cancer Center), Mark Schoenberg(Montefiore Medical Center), H. Barton Grossman(The University of Texas MD Anderson Cancer Center), Norm D. Smith(Caris Life Sciences (United States)), Tracy M. Downs(University of Wisconsin–Madison), Matthew J. Resnick(Vanderbilt University Medical Center), J. Alfred Witjes(Radboud University Nijmegen)
Cited by 83
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k